PHARMACEUTICAL DOSAGE FORMS COMPRISING 3-(5-METHYL-1,3-THIAZOL-2-YL)-5-[(3R)-TETRAHYDROFURAN-3-YLOXY]-N-{(1R)-1-[2-(TRIFLUOROMETHYL)PYRIMIDIN-5-YL]ETHYL}-BENZAMIDE

The present invention relates to a pharmaceutical dosage form containing an amorphous solid dispersion (ASD) comprising Eliapixant in a pharmaceutically acceptable matrix, its process of preparation and its use for treating disorders. La présente invention concerne une forme posologique pharmaceutiq...

Full description

Saved in:
Bibliographic Details
Main Authors KRICKAU, Dennis, TEREBESI, Ildiko
Format Patent
LanguageEnglish
French
Published 08.12.2022
Subjects
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
Online AccessGet full text

Cover

More Information
Summary:The present invention relates to a pharmaceutical dosage form containing an amorphous solid dispersion (ASD) comprising Eliapixant in a pharmaceutically acceptable matrix, its process of preparation and its use for treating disorders. La présente invention concerne une forme posologique pharmaceutique contenant une dispersion solide amorphe (ASD) comprenant de l'éliapixant dans une matrice pharmaceutiquement acceptable, son procédé de préparation et son utilisation pour le traitement de troubles.
Bibliography:Application Number: WO2022EP65018